accountrate of bleeding in a trial of patients with acute illnesses, representing a significant setback for the drugmakers. Bayer AG (BAYGn.DE Industry analysts had predicted the trial of rivaroxaban, if successful, would create a potential $2.8 billion-a-year...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Higher bleeding risk seen in J&J, Bayer clot drug
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account